Search results for "LI-RADS"

showing 10 items of 10 documents

Hepatocellular carcinoma (HCC) vs. non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018

2019

PURPOSE: The Liver Imaging Reporting and Data System (LI-RADS) was created to standardize the diagnostic criteria for hepatocellular carcinoma (HCC), and has undergone multiple revisions including a recent update in 2018 (v2018). The primary aim of this study was to determine the diagnostic performance and interrater reliability (IRR) of LI-RADS v2018 for distinguishing HCC from non-HCC primary hepatic malignancy in patients ‘at-risk’ for HCC. A secondary aim was to assess the impact of changes introduced in the v2018 diagnostic algorithm. METHODS: This retrospective study combined a 10-year experience of pathologically-proven primary liver malignancies from two large liver transplant cente…

AdultMalemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularUrologyMalignancySensitivity and SpecificityArticle030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineInternal medicineImage Interpretation Computer-AssistedmedicineHumansRadiology Nuclear Medicine and imagingIn patientLiver imagingAgedRetrospective StudiesAged 80 and overCirrhosiRadiological and Ultrasound Technologybusiness.industryLiver NeoplasmsGastroenterologyReproducibility of ResultsRetrospective cohort studyHepatologyMiddle Agedmedicine.diseaseMagnetic Resonance ImagingInterrater reliabilitydigestive system diseasesCombined hepatocellular-cholangiocarcinoma (cHCC-CCA)030220 oncology & carcinogenesisHepatocellular carcinomaCohortLI-RADSFemaleRadiologybusinessTomography X-Ray ComputedIntrahepatic cholangiocarcinoma (iCCA)Algorithms
researchProduct

Editorial Comment: LI-RADS Provides High Accuracy for Liver Transplant Eligibility in High-Risk Patients.

2022

Carcinoma HepatocellularHepatocellular carcinomaLiver NeoplasmsLI-RADSContrast MediaHumansRadiology Nuclear Medicine and imagingGeneral MedicineSettore MED/36 - Diagnostica Per Immagini E RadioterapiaTomography X-Ray ComputedMagnetic Resonance ImagingLiver TransplantationAJR. American journal of roentgenology
researchProduct

Outcome of LR-3 and LR-4 observations without arterial phase hyperenhancement at Gd-EOB-DTPA-enhanced MRI follow-up

2020

Objective: The aim of this study was to retrospectively analyze the outcome of LR-3 and LR-4 without arterial phase hyperenhancement (APHE), and identify which features could predict LR-5 progression on serial Gd-EOB-DTPA-enhanced MRI follow-up. Methods: Forty-nine cirrhotic patients with 55 LR-3 and 19 LR-4 without APHE were evaluated. Observations were classified as decreased, stable or increased in category at follow-up. Observation size and LI-RADS major and ancillary features were evaluated. Results: Seventeen/fifty-five (31%) LR-3 and 8/19 (42%) LR-4 progressed to LR-5 at follow-up. Baseline LI-RADS major and ancillary features were not significantly different among LR-3 and LR-4. A d…

Gadolinium DTPAGd-EOB-DTPA-enhanced MRILR-3Carcinoma HepatocellularLR-4business.industryLiver NeoplasmsGd-EOB-DTPAContrast MediaMagnetic Resonance Imaging030218 nuclear medicine & medical imagingSettore MED/01 - Statistica Medica03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisMedicineHumansLI-RADSRadiology Nuclear Medicine and imagingNuclear medicinebusinessSettore MED/36 - Diagnostica Per Immagini E RadioterapiaArterial phaseFollow-Up StudiesRetrospective Studies
researchProduct

Hepatobiliary phase hypointensity predicts progression to hepatocellular carcinoma for intermediate-high risk observations, but not time to progressi…

2020

Purpose: To determine whether hepatobiliary phase hypointensity, enhancing “capsule” and size provide prognostic information regarding the risk of progression to hepatocellular carcinoma (HCC), as well as the time to progression, of intermediate to high risk observations ≥ 10 mm with arterial phase hyperenhancement (APHE). Method: This retrospective dual-institution study included 160 LR-3 and 26 LR-4 observations measuring more than 10 mm and having APHE in 136 patients (mean age [SD], 57 [11] years old). A composite reference standard of pathologic analysis and imaging follow-up was used. The prognostic performance of hepatobiliary phase hypointensity, enhancing “capsule” and size (cut-of…

Gadolinium DTPAMalemedicine.medical_specialtyGadoxetic acidCarcinoma HepatocellularContrast MediaIndependent predictorGastroenterologyTime030218 nuclear medicine & medical imagingCohort Studies03 medical and health sciences0302 clinical medicineInternal medicineImage Interpretation Computer-AssistedmedicineHumansRadiology Nuclear Medicine and imagingReference standardsRetrospective StudiesObserver Variationbusiness.industryTime to progressionLiver NeoplasmsMean ageGeneral MedicineMiddle AgedImage EnhancementPrognosismedicine.diseaseMagnetic Resonance ImagingLiverGadoxetic acid LI-RADS Hepatobiliary phase Hepatocellular carcinoma030220 oncology & carcinogenesisHepatocellular carcinomaDisease ProgressionHepatobiliary phaseFemalebusinessFollow-Up StudiesArterial phasemedicine.drug
researchProduct

Radiomics Analysis on Gadoxetate Disodium-Enhanced MRI Predicts Response to Transarterial Embolization in Patients with HCC

2022

Objectives: To explore the potential of radiomics on gadoxetate disodium-enhanced MRI for predicting hepatocellular carcinoma (HCC) response after transarterial embolization (TAE). Methods: This retrospective study included cirrhotic patients treated with TAE for unifocal HCC naïve to treatments. Each patient underwent gadoxetate disodium-enhanced MRI. Radiomics analysis was performed by segmenting the lesions on portal venous (PVP), 3-min transitional, and 20-min hepatobiliary (HBP) phases. Clinical data, laboratory variables, and qualitative features based on LI-RADSv2018 were assessed. Reference standard was based on mRECIST response criteria. Two different radiomics models were construc…

LI-Clinical Biochemistryradiomicmagnetic resonance imaginghepatocellular carcinomatreatment response.radiomics; LI-RADS; hepatocellular carcinoma; magnetic resonance imaging; treatment response
researchProduct

Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules

2018

Background & Aims The use of contrast enhanced ultrasound (CEUS) for the diagnosis of hepatocellular carcinoma (HCC) in cirrhosis was questioned because of the risk of a false positive diagnosis in cases of cholangiocarcinoma. The American College of Radiology has recently released a scheme (CEUS Liver Imaging Reporting and Data System [LI-RADS®]) to classify lesions at risk of HCC investigated by CEUS. The aim of the present study was to validate this LI-RADS scheme for the diagnosis of HCC. Methods A total of 1,006 nodules from 848 patients with chronic liver disease at risk of HCC were collected in five Italian centers and retrospectively analyzed. Nodules were classified as LR-5, (HCC) …

Liver CirrhosisMaleCirrhosisContrast enhanced ultrasoundContrast MediaChronic liver diseaseGastroenterology030218 nuclear medicine & medical imagingCholangiocarcinoma0302 clinical medicineDiagnosisMedicineTomographyWashoutUltrasonographyUltrasoundLiver NeoplasmsMiddle AgedMagnetic Resonance ImagingX-Ray ComputedLiverHepatocellular carcinoma030211 gastroenterology & hepatologyFemaleRadiologymedicine.symptomAlgorithmsContrast-enhanced ultrasoundAdultmedicine.medical_specialtyCarcinoma HepatocellularDiagnosis Differential03 medical and health sciencesInternal medicineHumansDiagnostic ErrorsneoplasmsAgedLiver Imaging Reporting And Data System (LI-RADS)Hepatologybusiness.industryCarcinomaSettore MED/09 - MEDICINA INTERNAReproducibility of ResultsHepatocellularRetrospective cohort studyHistologyNodule (medicine)medicine.diseaseImage Enhancementdigestive system diseasesArterial hyperenhancementDifferentialbusinessTomography X-Ray Computed
researchProduct

Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals.

2021

Background & Aims The risk of progression of indeterminate observations to hepatocellular carcinoma (HCC) after direct-acting antivirals (DAA) is still undetermined. To assess whether DAA therapy changes the risk of progression of observations with low (LR-2), intermediate (LR-3) and high (LR-4) probability for HCC in cirrhotic patients and to identify predictors of progression. Methods This retrospective study included cirrhotic patients treated with DAA who achieved sustained virological response between 2015 and 2019. A total of 68 patients had pre-DAA indeterminate observations and at least six months CT/MRI follow-up before and after DAA. Two radiologists reviewed CT/MRI studies to…

Liver Cirrhosismedicine.medical_specialtyMultivariate analysisCirrhosisCarcinoma HepatocellularGastroenterologyAntiviral Agents03 medical and health sciences0302 clinical medicineInternal medicineMedicineHumansRetrospective StudiesHepatologybusiness.industryProportional hazards modelHazard ratioLiver NeoplasmsRetrospective cohort studyHepatitis CHepatitis C Chronicmedicine.diseaseMagnetic Resonance Imaging030220 oncology & carcinogenesisHepatocellular carcinomaLI-RADS030211 gastroenterology & hepatologybusinessIndeterminateLiver international : official journal of the International Association for the Study of the LiverREFERENCES
researchProduct

Reply to “Letter to the editor”

2019

LiverRadiological and Ultrasound TechnologyHepatocellular carcinomaUrologyGastroenterologyHumansLI-RADSRadiology Nuclear Medicine and imagingSettore MED/36 - Diagnostica Per Immagini E Radioterapia
researchProduct

Expanding the Liver Imaging Reporting and Data System (LI-RADS) v2018 diagnostic population: performance and reliability of LI-RADS for distinguishin…

2018

Abstract Background Hepatocellular carcinoma (HCC) can be diagnosed using imaging criteria in patients at high-risk for HCC, according to Liver Imaging Reporting and Data System (LI-RADS) guidelines. The aim of this study was to determine the diagnostic performance and inter-rater reliability (IRR) of LI-RADS v2018 for differentiating HCC from non-HCC primary liver carcinoma (PLC), in patients who are at increased risk for HCC but not included in the LI-RADS ‘high-risk’ population. Methods This retrospective HIPAA-compliant study included a 10-year experience of pathologically-proven PLC at two liver transplant centers, and included patients with non-cirrhotic hepatitis C infection, non-cir…

OncologyMalemedicine.medical_specialtyCarcinoma HepatocellularPopulationSensitivity and SpecificityCholangiocarcinoma03 medical and health sciences0302 clinical medicineInternal medicineCarcinomaMedicineData SystemsHumanseducationneoplasmsAgedRetrospective Studieseducation.field_of_studyLI-RADS Hepatocellular carcinomaHepatologymedicine.diagnostic_testbusiness.industryFatty liverLiver NeoplasmsGastroenterologyReproducibility of ResultsMagnetic resonance imagingRetrospective cohort studyHepatitis CHepatitis C Chronicmedicine.diseaseMagnetic Resonance Imagingdigestive system diseasesFatty Liver030220 oncology & carcinogenesisHepatocellular carcinomaCohort030211 gastroenterology & hepatologyFemalebusinessTomography X-Ray ComputedSettore MED/36 - Diagnostica Per Immagini E Radioterapia
researchProduct

Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS

2021

Background & Aims The histopathological subtypes of hepatocellular carcinoma (HCC) are associated with distinct clinical features and prognoses. This study aims to report Liver Imaging Reporting and Data System (LI-RADS)-defined imaging features of different HCC subtypes in a cohort of resected tumours and to assess the influence of HCC subtypes on computed tomography (CT)/magnetic resonance imaging (MRI) LI-RADS categorisation in the subgroup of high-risk patients. Methods This retrospective institutional review board-approved study included patients with resected HCCs and available histopathological classification. Three radiologists independently reviewed preoperative CT and MRI exams. T…

medicine.medical_specialtyHepatocellular carcinomaALT alanine transaminaseComputed tomographyRC799-869AST aspartate aminotransferaseOS overall survivalHistopathological subtypeMagnetic resonance imagingNOS-HCC not otherwise specified hepatocellular carcinomaInternal MedicinemedicineImmunology and AllergyIn patientComputed tomographyLI-RADS Liver Imaging Reporting and Data SystemLiver imagingHepatologymedicine.diagnostic_testbiologyUS ultrasoundbusiness.industryNot Otherwise SpecifiedGastroenterologyTIV tumour-in-veinMagnetic resonance imagingHBP hepatobiliary phaseDiseases of the digestive system. Gastroenterologymedicine.diseasedigestive system diseasesHistopathological subtypesCT computed tomographyRFS recurrence-free survivalAlanine transaminaseHepatocellular carcinomaSH-HCC steatohepatitic hepatocellular carcinomaCohortMTM-HCC macrotrabecular-massive hepatocellular carcinomabiology.proteinLI-RADSRadiologyAPHE arterial phase hyperenhancementbusinessHCC hepatocellular carcinomaMRI magnetic resonance imagingResearch ArticleJHEP Reports
researchProduct